{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:57:44Z","timestamp":1787162264431,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10157-012-0684-5","type":"journal-article","created":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:01:00Z","timestamp":1347408060000},"page":"659-671","source":"Crossref","is-referenced-by-count":19,"title":["Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion"],"prefix":"10.1007","volume":"16","author":[{"given":"Kenshi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,13]]},"reference":[{"key":"684_CR1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","volume":"82","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323\u201341.","journal-title":"Mayo Clin Proc"},{"key":"684_CR2","doi-asserted-by":"crossref","unstructured":"Bergsagel DE, et al. Myeloma proteins and the clinical response to melphalan therapy. Science. 1965;148(3668):376\u20137.","DOI":"10.1126\/science.148.3668.376"},{"key":"684_CR3","first-page":"179","volume":"51","author":"SC Salmon","year":"1967","unstructured":"Salmon SC, et al. Intermittent high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179\u201387.","journal-title":"Cancer Chemother Rep"},{"issue":"9","key":"684_CR4","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680\u20135.","journal-title":"JAMA"},{"key":"684_CR5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"684_CR6","doi-asserted-by":"crossref","unstructured":"San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317.","DOI":"10.1056\/NEJMoa0801479"},{"issue":"5","key":"684_CR7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516\u201320.","journal-title":"Blood"},{"issue":"24 Pt 1","key":"684_CR8","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1158\/1078-0432.CCR-05-2305","volume":"11","author":"T Hideshima","year":"2005","unstructured":"Hideshima T, et al. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005;11(24 Pt 1):8530\u20133.","journal-title":"Clin Cancer Res"},{"key":"684_CR9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","volume":"118","author":"PM Fayers","year":"2011","unstructured":"Fayers PM, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239\u201347.","journal-title":"Blood"},{"key":"684_CR10","doi-asserted-by":"crossref","unstructured":"Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","DOI":"10.1056\/NEJMoa043445"},{"key":"684_CR11","unstructured":"San Miguel JF, et al. ASH2011. http:\/\/myeloma.org\/pdfs\/ASH2011_San%20Miguel_3619.pdf ."},{"key":"684_CR12","unstructured":"Suzuki K. Discovery research on the effects of giving continuity to the administration of bortezomib in maintenance therapy to target of relapsed and refractory multiple myeloma. J New Rem Clin. 2012;61:1259\u201369."},{"key":"684_CR13","doi-asserted-by":"crossref","unstructured":"Durie BGM, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","DOI":"10.1038\/sj.leu.2404284"},{"issue":"1","key":"684_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","volume":"143","author":"R Niesvizky","year":"2008","unstructured":"Niesvizky R, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46\u201353.","journal-title":"Br J Haematol"},{"issue":"15","key":"684_CR15","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, et al. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139\u201346.","journal-title":"Blood"},{"issue":"15","key":"684_CR16","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","volume":"28","author":"A Chanan-Khan","year":"2010","unstructured":"Chanan-Khan A, et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612\u201324.","journal-title":"J Clin Oncol"},{"key":"684_CR17","doi-asserted-by":"crossref","unstructured":"Palumbo A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood. 2008;112(8):3107\u201314.","DOI":"10.1182\/blood-2008-04-149427"},{"key":"684_CR18","doi-asserted-by":"crossref","unstructured":"Facon T, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209\u201318.","DOI":"10.1016\/S0140-6736(07)61537-2"},{"issue":"22","key":"684_CR19","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol. 2009;27(22):3664\u201370.","journal-title":"J Clin Oncol"},{"key":"684_CR20","unstructured":"Rajkmar SV, et al. ASH 2008 joint ASH\/ASCO symposium."},{"issue":"2","key":"684_CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","volume":"5","author":"MA Dimopoulos","year":"2004","unstructured":"Dimopoulos MA, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112\u20137.","journal-title":"Hematol J"},{"issue":"4","key":"684_CR22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","volume":"18","author":"R Garcia-Sanz","year":"2004","unstructured":"Garcia-Sanz R, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma. Leukemia. 2004;18(4):856\u201363.","journal-title":"Leukemia"},{"issue":"6","key":"684_CR23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","volume":"129","author":"C Kyriakou","year":"2005","unstructured":"Kyriakou C, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129(6):763\u201370.","journal-title":"Br J Haematol"},{"key":"684_CR24","doi-asserted-by":"crossref","unstructured":"Palumbo A, et al. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","DOI":"10.1056\/NEJMra1011442"},{"key":"684_CR25","doi-asserted-by":"crossref","unstructured":"Ladetto M, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077\u201384.","DOI":"10.1200\/JCO.2009.23.7172"},{"key":"684_CR26","doi-asserted-by":"crossref","unstructured":"Cave M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9\u201319.","DOI":"10.1182\/blood-2012-02-408898"},{"key":"684_CR27","doi-asserted-by":"crossref","unstructured":"Abderrahman A, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805\u201310.","DOI":"10.1182\/blood-2007-07-101212"},{"key":"684_CR28","doi-asserted-by":"crossref","unstructured":"Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565\u201371.","DOI":"10.1056\/NEJM199911183412102"},{"key":"684_CR29","unstructured":"Suzuki K, et al. Maintenance therapy of bortezomib-dexa (BzDx) for multiple myeloma. Clin Hematol. 2010;51(9):1181."},{"issue":"19","key":"684_CR30","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"19","key":"684_CR31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759\u201369.","journal-title":"N Engl J Med"},{"key":"684_CR32","unstructured":"Reece DE, et al. ASH2010 Poster #1877."},{"key":"684_CR33","unstructured":"Abe Y, Suzuki K, et al. Abstract PS-2-26 (1264) 498. Japan Society of Hematology; 2011."},{"key":"684_CR34","unstructured":"Treatment guidance of multiple myeloma. 2nd ed. Japanese Society of Myeloma; 2008."},{"key":"684_CR35","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889\u201393.","journal-title":"Arch Intern Med"},{"key":"684_CR36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","volume":"34","author":"M Roussou","year":"2010","unstructured":"Roussou M, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34:1395\u20137.","journal-title":"Leuk Res"},{"key":"684_CR37","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","volume":"116","author":"M Dimopoulos","year":"2010","unstructured":"Dimopoulos M, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116:3807\u201314.","journal-title":"Cancer"},{"key":"684_CR38","unstructured":"Revlimid Capsules Package Insert. http:\/\/www.revlimid-japan.jp\/professional\/product\/pdf\/pi\/pi_rev_201201.pdf ."},{"key":"684_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01461.x","volume":"85","author":"M Dimopoulos","year":"2010","unstructured":"Dimopoulos M, et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1\u20135.","journal-title":"Eur J Haematol"},{"key":"684_CR40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","volume":"90","author":"U Klein","year":"2011","unstructured":"Klein U, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90:429\u201339.","journal-title":"Ann Hematol"},{"key":"684_CR41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-0609.2010.01500.x","volume":"85","author":"De Rubia la","year":"2011","unstructured":"la Rubia De, et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol. 2011;85:363\u20135.","journal-title":"Eur J Haematol"},{"key":"684_CR42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","volume":"25","author":"M Dimopoulos","year":"2011","unstructured":"Dimopoulos M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749\u201360.","journal-title":"Leukemia"},{"key":"684_CR43","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","volume":"116","author":"S Kumar","year":"2010","unstructured":"Kumar S, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126\u20139.","journal-title":"Blood"},{"key":"684_CR44","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","volume":"103","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case\u2013control study. Blood. 2004;103:3960.","journal-title":"Blood"},{"key":"684_CR45","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","volume":"110","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561.","journal-title":"Blood"},{"key":"684_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85.","journal-title":"Ann Intern Med"},{"key":"684_CR47","doi-asserted-by":"crossref","unstructured":"Merlini G, et al. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924\u201333.","DOI":"10.1200\/JCO.2010.32.2271"},{"key":"684_CR48","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","volume":"118","author":"MT Cibelia","year":"2011","unstructured":"Cibelia MT, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346\u201352.","journal-title":"Blood"},{"key":"684_CR49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","volume":"119","author":"B Madan","year":"2012","unstructured":"Madan B, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117\u201322.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10157-012-0684-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T20:03:21Z","timestamp":1497989001000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-012-0684-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,13]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s10157-012-0684-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,13]]}}}